Airway Therapeutics’ IND application for AT-100 gets FDA acceptance to treat Covid-19

The firm is leveraging the FDA’s Coronavirus Treatment Acceleration Program (CTAP), which is aimed at evaluating new treatments options for Covid-19 disease. Credit: Gerd Altmann from Pixabay